文献速递胸部肿瘤

基于病理医师的前瞻性多机构研究:四种免疫组化检测非小细胞肺癌PD-L1表达的评估

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2017-01-01

该前瞻性多机构研究比较了四种PD-L1免疫组化检测平台在90例非小细胞肺癌组织切片上的表现,由13位病理医师评分。结果显示SP142检测在肿瘤和免疫细胞中PD-L1表达均显著较低,22c3较28-8和E1L3N略低但仅在使用13位病理医师评分均值时具统计学意义;肿瘤细胞评分一致性高,免疫细胞评分一致性差。

要点

  • SP142检测在肿瘤和免疫细胞中PD-L1表达均显著低于其他三种检测。
  • 22c3检测肿瘤细胞PD-L1表达较28-8和E1L3N略低但具统计学意义。
  • 病理医师对肿瘤细胞PD-L1评分一致性高,对免疫细胞评分一致性差。

核心结论

  • 使用SP142抗体的检测为异常值,检测到的肿瘤细胞和免疫细胞PD-L1表达显著较低。
  • 22c3抗体检测染色略低于28-8或E1L3N,但仅在使用13位病理医师评分均值时具统计学意义。
  • 病理医师对任何抗体染色的肿瘤细胞评分一致性极好,但对免疫细胞评分一致性差。
  • 因此,对于肿瘤细胞PD-L1评估,四种检测中有三种在病理医师判读下结果一致且可重复。

研究设计与样本

  • 前瞻性多机构研究,纳入2008年1月1日至2010年12月31日期间的90例存档非小细胞肺癌连续组织切片。
  • 切片分发至3个站点,分别进行28-8抗体(Dako Link 48平台)、22c3抗体(Dako Link 48平台)、SP142抗体(Ventana Benchmark平台)和E1L3N抗体(Leica Bond平台)免疫组化检测。
  • 切片扫描后由13位病理医师评分,估计表达PD-L1的恶性细胞和免疫细胞百分比。
  • 统计分析于2015年12月1日至2016年8月30日进行,比较抗体间及病理医师间对肿瘤和免疫细胞评分的差异。

主要发现

  • 在90例样本中,SP142检测为异常值,肿瘤细胞平均评分:22c3为2.96,28-8为3.26,SP142为1.99,E1L3N为3.20,总体均值为2.85。
  • 免疫细胞平均评分:22c3为2.15,28-8为2.28,SP142为1.62,E1L3N为2.28,总体均值为2.08。
  • 两两比较显示28-8与E1L3N评分无显著差异,22c3检测肿瘤细胞PD-L1表达标记略低(平均差异0.24-0.30)但具统计学意义。
  • 抗体间肿瘤细胞评分组内相关系数(ICC)为0.813(95%CI 0.815-0.839),免疫细胞评分ICC为0.277(95%CI 0.222-0.334)。
  • 任一检测中病理医师间肿瘤细胞评分ICC范围为0.832(95%CI 0.820-0.844)至0.882(95%CI 0.873-0.891),免疫细胞评分ICC范围为0.172(95%CI 0.156-0.189)至0.229(95%CI 0.211-0.248)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Four assays registered with the US Food and Drug Administration (FDA) detect programmed cell death ligand 1 (PD-L1) to enrich for patient response to anti-programmed cell death 1 and anti-PD-L1 therapies. The tests use 4 separate PD-L1 antibodies on 2 separate staining platforms and have their own scoring systems, which raises questions about their similarity and the potential interchangeability of the tests. OBJECTIVE: To compare the performance of 4 PD-L1 platforms, including 2 FDA-cleared assays, 1 test for investigational use only, and 1 laboratory-developed test. DESIGN, SETTING, AND PARTICIPANTS: Four serial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to December 31, 2010, were distributed to 3 sites that performed the following immunohistochemical assays: 28-8 antibody on the Dako Link 48 platform, 22c3 antibody on the Dako Link 48 platform, SP142 antibody on the Ventana Benchmark platform, and E1L3N antibody on the Leica Bond platform. The slides were scanned and scored by 13 pathologists who estimated the percentage of malignant and immune cells expressing PD-L1. Statistical analyses were performed from December 1, 2015, to August 30, 2016, to compare antibodies and pathologists' scoring of tumor and immune cells. MAIN OUTCOMES AND MEASURES: Percentages of malignant and immune cells expressing PD-L1. RESULTS: Among the 90 samples, the SP142 assay was an outlier, with a significantly lower mean score of PD-L1 expression in both tumor and immune cells (tumor cells: 22c3, 2.96; 28-8, 3.26; SP142, 1.99; E1L3N, 3.20; overall mean, 2.85; and immune cells: 22c3, 2.15; 28-8, 2.28; SP142, 1.62; E1L3N, 2.28; overall mean, 2.08). Pairwise comparisons showed that the scores from the 28-8 and E1L3N tests were not significantly different but that the 22c3 test showed a slight (mean difference, 0.24-0.30) but statistically significant reduction in labeling of PD-L1 expression in tumor cells. Evaluation of intraclass correlation coefficients (ICCs) between antibodies to quantify interassay variability for PD-L1 expression in tumor cells showed high concordance between antibodies for tumor cell scoring (0.813; 95% CI, 0.815-0.839) and lower levels of concordance for immune cell scoring (0.277; 95% CI, 0.222-0.334). When examining variability between pathologists for any single assay, the concordance between pathologists' scoring for PD-L1 expression in tumor cells ranged from ICCs of 0.832 (95% CI, 0.820-0.844) to 0.882 (95% CI, 0.873-0.891) for each assay, while the ICCs from immune cells for each assay ranged from 0.172 (95% CI, 0.156-0.189) to 0.229 (95% CI, 0.211-0.248). CONCLUSIONS AND RELEVANCE: The assay using the SP142 antibody is an outlier that detected significantly less PD-L1 expression in tumor cells and immune cells. The assay for antibody 22c3 showed slight yet statistically significantly lower staining than either 28-8 or E1L3N, but this significance was detected only when using the mean of 13 pathologists' scores. The pathologists showed excellent concordance when scoring tumor cells stained with any antibody but poor concordance for scoring immune cells stained with any antibody. Thus, for tumor cell assessment of PD-L1, 3 of the 4 tests are concordant and reproducible as read by pathologists.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Rimm DL, Han G, Taube JM, et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017. PMID: 28278348. doi:10.1001/jamaoncol.2017.0013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。